Summary
This Form 6-K filing by CRH Public Limited Company (CRH) reports on transactions by persons discharging managerial responsibilities (PDMRs) and directors related to their shareholdings and options. Specifically, it details the grant of new options under the company's Savings-related Share Option Scheme to Myles P. Lee, Jack Golden, Liam Hughes, and Albert Manifold, as well as the lapse of some previously granted options for Mr. Golden, Mr. Hughes, and Mr. Manifold. These grants and lapses are standard equity-based compensation practices and provide insight into management's ongoing participation in the company's equity.
Key Highlights
- 1The filing discloses the grant of new share options under CRH's Savings-related Share Option Scheme to four key individuals: Myles P. Lee, Jack Golden, Liam Hughes, and Albert Manifold.
- 2The exercise price for these newly granted options is set at €20.40 per ordinary share.
- 3Options granted to Myles P. Lee and Albert Manifold are exercisable between July 1, 2013, and December 31, 2013.
- 4Options granted to Jack Golden and Liam Hughes are exercisable between July 1, 2011, and December 31, 2011.
- 5The filing also notes the lapse of previously granted options for Jack Golden (874 shares), Liam Hughes (436 shares), and Albert Manifold (753 shares) under the same scheme.
- 6These transactions are considered in accordance with Market Abuse Rules and relevant UK Companies Act sections.
- 7The disclosure reflects ongoing equity incentive programs for CRH's senior management.
Frequently Asked Questions
This filing (Form 6-K) is a report of a foreign issuer and specifically details transactions by CRH's directors and persons discharging managerial responsibilities (PDMRs) concerning their shareholdings and options. It ensures transparency regarding insider transactions in accordance with regulatory requirements.
The report details the grant of new share options under CRH's Savings-related Share Option Scheme to several PDMRs and directors. It also notes the lapse of some previously granted options for certain individuals.
The exercise price of €20.40 per ordinary share is the fixed price at which the PDMRs or directors can purchase the CRH shares once their options vest and are exercisable. This provides them with a potential profit if the market price of CRH shares rises above this level.
Not necessarily. Options can lapse for various reasons, including failure to meet certain vesting conditions or simply because the specified exercise window has passed without the option being exercised. In this context, it appears to be a routine part of managing the company's equity incentive programs, rather than an indicator of distress.